Skip to main content
SpringerLink
Log in

RNA–drug interactions

RNA as an off-target for FDA-approved drugs

  • News & Views
  • Published:

From Nature Chemistry

View current issue Submit your manuscript

Medicinal chemistry efforts typically focus on drug–protein interactions and overlook RNA binding as a source of off-target pharmacology. Now, a new method has been developed to map the interactions of small-molecule drugs with RNA in cells and characterize how these interactions can exert functional effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Reactivity-based RNA profiling of FDA-approved drugs reveals off-target transcriptome interactions that may contribute to side effects and dose-limiting toxicity.

References

  1. Falese, J. P. et al. Chem. Soc. Rev. 50, 2224–2243 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Yazdani, K. et al. Angew. Chem. 135, e202211358 (2023).

    Article  Google Scholar 

  3. Sheridan, C. Nat. Biotechnol. 39, 6–8 (2021).

    Article  CAS  PubMed  Google Scholar 

  4. Zhang, P. et al. J. Am. Chem. Soc. 143, 13044–13055 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Huang, S. et al. Nat. Commun. 13, 2413 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Fang, L. et al. Nat. Chem. https://doi.org/10.1038/s41557-023-01309-8 (2023).

    Article  PubMed  Google Scholar 

  7. Weeks, K. M. Acc. Chem. Res. 54, 2502–2517 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Bennett, A. C. et al. Expert Opin. Drug Saf. 18, 1055–1063 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Flynn, R. A. Nat. Protoc. 11, 273–290 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chemical Biology Laboratory, National Cancer Institute, Frederick, MD, USA

    Christopher R. Fullenkamp & John S. Schneekloth Jr

Authors
  1. Christopher R. Fullenkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John S. Schneekloth Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John S. Schneekloth Jr.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fullenkamp, C.R., Schneekloth, J.S. RNA as an off-target for FDA-approved drugs. Nat. Chem. 15, 1329–1331 (2023). https://doi.org/10.1038/s41557-023-01330-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41557-023-01330-x

  • Springer Nature Limited

Search

Navigation